Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese Participants.
健康的日本人和非日本人參與者中Cilofexor和Firsocostat的藥物代謝動力學及安全性。
J Clin Pharmacol 2024-08-30
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
BI 456906,一種雙胰高血糖素受體/類胰高血糖素-1受體激動劑,在超重/肥胖的日本男性健康受試者中的安全性、耐受性、藥物動力學和藥效動力學的隨機I期研究。
Diabetes Obes Metab 2023-06-06
Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m<sup>2</sup> or higher: A phase I, randomized, double-blind, placebo-controlled study.
600微克 Cotadutide 在日本第2型糖尿病患者中的安全性/耐受性、有效性和藥物動力學:一項階段I、隨機、雙盲、安慰劑對照研究。
Diabetes Obes Metab 2023-07-14
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
一項IIa期主動對照研究,評估 Efinopegdutide 在非酒精性脂肪肝患者中的療效和安全性。
J Hepatol 2023-09-22
Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
評估餐型和降酸劑對選擇性非類固醇類類固醇類固醇X受體激動劑Cilofexor藥物動力學的影響。
Clin Pharmacol Drug Dev 2024-02-12
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Efruxifermin與GLP-1受體激動劑聯合治療對NASH/MASH和2型糖尿病患者的安全性和有效性:隨機2期研究。
Clin Gastroenterol Hepatol 2024-04-07
Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Proline Henagliflozin in Chinese Subjects with Varying Degrees of Liver Dysfunction.
Proline Henagliflozin在不同程度肝功能異常的中國受試者中的藥物動力學、藥效學和安全性概況。
J Clin Pharmacol 2024-04-30
A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
一項階段1的、隨機分配、雙盲、安慰劑對照試驗,探討口服semaglutide在健康中國受試者中的藥代動力學、藥效動力學、安全性和耐受性。
Diabetes Obes Metab 2024-05-29
Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice.
日本2型糖尿病患者中tofogliflozin的安全性和有效性:一項在常規臨床實踐中的多中心前瞻性觀察研究。
J Diabetes Investig 2024-08-14
Racial Comparison of the Pharmacokinetics and Safety of Fixed-Dose Combination of Dapagliflozin/Sitagliptin in Western and Korean Healthy Adults.
西方與韓國健康成人中 Dapagliflozin/Sitagliptin 固定劑量聯合用藥的藥物動力學及安全性之種族比較。
Clin Ther 2024-08-23
Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients.
對於日本2型糖尿病患者,鈉-葡萄糖共轉運蛋白-2抑制劑對代謝功能障礙相關脂肪肝疾病發展的長期影響之回顧性縱向觀察研究。
J Clin Med 2024-08-29